Steve Shak

Chief Medical Officer

Joined Exact Sciences: 2019

Key Responsibility: Lead strategy for the company's clinical development plans, building relationships with key leaders and institutions in the cancer community, and ensuring the voice of patients and physicians are heard at all levels of the organization.

Previous Employment: Co-Founder, Chief Medical Officer, and Chief Scientific Officer at Genomic Health driving Oncotype DX assay development in breast, prostate and colon cancer. Research Director and Staff Clinical Scientist at Genentech, leading the clinical team in the development of the targeted breast cancer drug Herceptin®, and the research team in the discovery of the cystic fibrosis drug Pulmozyme®. Assistant Professor of Medicine and Pharmacology at New York University School of Medicine.

Education: MD, New York University School of Medicine; post-doctoral training at Bellevue Hospital and the University of California, San Francisco; BA, Amherst College

7Asset 1

"We urgently need new and more effective approaches to cancer diagnosis, treatment, and prevention. In the 20th century, with few diagnostic tests to select the right treatment for individual cancers, physicians treated cancer with a “one-size-fits-all” approach. We passionately believe that cancer molecular diagnostics will play an indispensable role in treatment planning for all cancer patients and will help turn cancer into a manageable, and ultimately preventable, disease."